BioCapital

Found 41,692 articles

• Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2022 Financial Results on March 27, 2023

  3/20/2023

  Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report fourth quarter and year-end 2022 financial results on Monday, March 27, 2023.

• Northwest Biotherapeutics and Advent BioServices Announce Receipt of License for Commercial Manufacturing at Sawston, U.K. Facility

  3/20/2023

  Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio") and Advent BioServices jointly announce that a MIA license has been approved and issued by the Medicines and Healthcare Products Regulatory Agency (MHRA) for commercial manufacturing of cell therapy products at the GMP facility in Sawston, U.K.

• MyMD Pharmaceuticals® and Charles River Present Positive Data for Next Generation, Oral TNF-α Inhibitor MYMD-1® in Rheumatoid Arthritis

  3/20/2023

  MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”) is presenting data from a preclinical study of investigational, oral TNF-α inhibitor MYMD-1® at the 2023 Society of Toxicology Annual Meeting (SOT) in Nashville, TN.

• Sirnaomics to Present Latest Developments in Polypeptide Nanoparticle Platform at the 4th Annual RNAi-Based Therapeutics Summit

  3/20/2023

  Sirnaomics Ltd. (the "Company", Stock Code: 2257.HK, and together with its subsidiaries, the "Group" or "Sirnaomics") announced today that Dr. Patrick Lu, Chairman of the Board, Executive Director, President and Chief Executive Officer and Dr. Richard W. Welch, Vice President of  Chemistry, Manufacturing, and Controls processes (CMC), will deliver keynote speeches during the 4th Annual RNAi-Based Therapeutic Summit.

• Altoida Announces Upcoming Poster Presentations at AD/PD 2023

  3/20/2023

  Altoida, Inc. today announced two poster presentations at the upcoming AD/PD™ 2023 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders, on March 28–April 1, 2023 in Gothenburg, Sweden.

• Innovent Announces Clinical Data of Multiple Trials Will be Presented at the AACR Annual Meeting 2023

  3/20/2023

  Innovent Biologics, Inc. ("Innovent") (HKEX: 01801) today announced that clinical data from multiple trials in relation to TYVYT® (sintilimab injection), Pemazyre® (pemigatinib) and IBI351 (KRASG12C inhibitor) will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, April 14 - 19, 2023.

• Theriva Biologics to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results

  3/20/2023

  Theriva Biologics (NYSE American: TOVX) today announced that it plans to host a conference call on Monday, March 27, 2023, at 8:30 a.m. ET to discuss its financial results for the fourth quarter and full-year ended December 31, 2022 and provide a corporate update.

• California Selects Civica Rx as Its Insulin Manufacturing Partner

  3/18/2023

  Civica Inc. announced it will manufacture insulins for the State of California’s CalRx Biosimilar Insulin Initiative as part of its insulin manufacturing work.

• Incyte Announces Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo

  3/18/2023

  Incyte announced new data from a Phase 2b clinical trial evaluating the safety and efficacy of povorcitinib, an investigational oral JAK1 inhibitor, in adult patients with extensive nonsegmental vitiligo.

• Incyte Announces Long-Term Extension Data from Phase 3 TRuE-V Program Demonstrating Long-Term Safety and Durability of Response of Opzelura® (Ruxolitinib) Cream in Vitiligo

  3/18/2023

  Incyte announced new 104-week results from the pivotal Phase 3 TRuE-V clinical trial program evaluating Opzelura® cream 1.5% in patients 12 years of age and older with nonsegmental vitiligo, a chronic autoimmune disease characterized by depigmentation of skin.

• FDA Roundup: March 17, 2023

  3/17/2023

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

• Processa Pharmaceuticals Announces First Patient Dosed in the 300 mg Dose Group with Next Generation Chemotherapy-Capecitabine

  3/17/2023

  Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a developer of Next Generation Chemotherapies (NGCs), today announced that the Company has dosed the first patient in its NGC-Capecitabine (combination of PCS6422 and capecitabine) 300 mg dose group.

• USPTO Issues Notice of Allowance to BRAINBox Solutions to Grant Broad U.S. Patent Covering Biomarkers that Correlate to MRI Neuroimaging Findings

  3/17/2023

  BRAINBox Solutions today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance to issue to the company a broad patent covering a specific set of biomarkers that correlate to specific neuroimaging findings by standard or advanced MRI methods.

• Zephyr AI and KangarooHealth Announce Partnership to Harness the Power of Remote Patient Monitoring and Artificial Intelligence

  3/16/2023

  Zephyr AI, Inc. (“Zephyr AI”) and KangarooHealth, Inc. (“KangarooHealth”) announced today a multi-year strategic partnership to work toward providing clinicians with insights to inform treatment decisions for patients diagnosed with chronic conditions.

• GlycoMimetics to Report Fourth Quarter and 2022 Full Year Financial Results on March 29, 2023

  3/16/2023

  GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report fourth quarter and 2022 full year financial results on Wednesday, March 29, 2023, at 8:30 a.m. ET.

• Clinical Geneticist Dr. Reed Pyeritz Receives 2023 David L. Rimoin Lifetime Achievement Award in Medical Genetics from the ACMG Foundation for Genetic and Genomic Medicine

  3/15/2023

  Internationally acclaimed clinical geneticist Reed Pyeritz, MD, PhD, FACMG, is the recipient of the 2023 ACMG Foundation for Genetic and Genomic Medicine's David L. Rimoin Lifetime Achievement Award in Medical Genetics.

• Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers

  3/15/2023

  Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced a clinical trial collaboration with BeiGene, for future evaluation of its investigational CDK9 inhibitor, PRT2527, in combination with BeiGene’s BTK inhibitor, zanubrutinib, in hematologic malignancies.

• HanAll Biopharma Opens Applications for the 2023 Pharmaceutical Industry Fellowship Program

  3/15/2023

  HanAll Biopharma Co., Ltd. is now accepting applications for the 2023 pharmaceutical industry fellowship program through April 15, 2023.

• Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results

  3/15/2023

  Senseonics Holdings, Inc., a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring systems for people with diabetes, reported financial results for the quarter and full year ended December 31, 2022.

•  54gene Announces Leadership Changes in Mission to Transform Diversity of Genomics Research Data

  3/15/2023

  54gene, Inc. today announced leadership changes that position the company to pursue new strategic partnerships and raise additional capital.